Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine exposure during lymphodepletion before CAR-T cell therapy
2025-524278-40-00Phase 4Authorised
- Sponsor
- Ghent University Hospital
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fludarabine in hematopoietic malignancies, sponsored by Ghent University Hospital. Primary endpoints: Area under concentration time curve (AUC) of F-Ara-A from time 0 to infinity, Coefficient of variation (CV) for plasma concentrations of F-Ara-A and 1 more. Planned start Mar 2026; status: authorised.
02
Drugs
fludarabine
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on 2025-524278-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524278-40-00.